Loading…

Bone marrow mesenchymal stem cell transplantation downregulates plasma level and the microglia expression of transforming growth factor β1 in the acute phase of cerebral cortex ischemia

Both bone marrow mesenchymal stem cell (BM-MSC) and transforming growth factor-β1 (TGF-β1) have a strong anti-inflammatory capacity in stroke. But their relationship has not been well addressed. In this study, we investigated how intravenous BM-MSC transplantation in rats effected the expression of...

Full description

Saved in:
Bibliographic Details
Published in:Chronic diseases and translational medicine 2020-12, Vol.6 (4), p.270-280
Main Authors: Liang, Zhao-Hui, Gu, Jian-Juan, Yu, Wen-Xiu, Guan, Yun-Qian, Khater, Mostafa, Li, Xiao-Bo
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4880-c6553da3ea7daa9013f9c17e8ace18c9aa5c8fc9522d83d3c49ce9e0f11e30793
cites cdi_FETCH-LOGICAL-c4880-c6553da3ea7daa9013f9c17e8ace18c9aa5c8fc9522d83d3c49ce9e0f11e30793
container_end_page 280
container_issue 4
container_start_page 270
container_title Chronic diseases and translational medicine
container_volume 6
creator Liang, Zhao-Hui
Gu, Jian-Juan
Yu, Wen-Xiu
Guan, Yun-Qian
Khater, Mostafa
Li, Xiao-Bo
description Both bone marrow mesenchymal stem cell (BM-MSC) and transforming growth factor-β1 (TGF-β1) have a strong anti-inflammatory capacity in stroke. But their relationship has not been well addressed. In this study, we investigated how intravenous BM-MSC transplantation in rats effected the expression of TGF-β1 48 h post cerebral ischemia, and we analyzed the main cells that produce TGF-β1. We used a distal middle cerebral artery occlusion (dMCAO) model in twenty Sprague–Dawley (SD) rats. The rats were randomly divided into two groups: the ischemic control group and the postischemic BM-MSC transplantation group. One hour after the dMCAO model was established, the rats were injected in the tail vein with either 1 ml saline or 1 × 106 BM-MSCs suspended in 1 ml saline. ELISAs were used to detect TGF-β1 content in the brain infarct core area, striatum and the plasma at 48 h after cerebral infarction. Immunofluorescent staining of brain tissue sections for TGF-β1, Iba-1, CD68 and NeuN was performed to determine the number and the proportion of double stained cells and to detect possible TGF-β1 producing cells in the brain tissue. Forty-eight hours after ischemia, the TGF-β1 content in the infarcted area of the BM-MSC transplantation group (23.94 ± 4.48 pg/ml) was significantly lower than it was in the ischemic control group (34.18 ± 4.32 pg/ml) (F = 13.534, P = 0.006). The TGF-β1 content in the rat plasma in the BM-MSC transplantation group (75.91 ± 12.53 pg/ml) was significantly lower than it was in the ischemic control group (131.18 ± 16.07 pg/ml) (F = 36.779, P = 0.0002), suggesting that after transplantation of BM-MSCs, TGF-β1 levels in the plasma decreased, but there was no significant change in the striatum area. Immunofluorescence staining showed that the total number of nucleated cells (1037.67 ± 222.16 cells/mm2) in the infarcted area after transplantation was significantly higher than that in the ischemic control group (391.67 ± 69.50 cells/mm2) (F = 92.421, P 
doi_str_mv 10.1016/j.cdtm.2020.05.005
format article
fullrecord <record><control><sourceid>wiley_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d1f9cdd7546e487ea4524796439a2080</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2095882X2030044X</els_id><doaj_id>oai_doaj_org_article_d1f9cdd7546e487ea4524796439a2080</doaj_id><sourcerecordid>CDT3BF00540</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4880-c6553da3ea7daa9013f9c17e8ace18c9aa5c8fc9522d83d3c49ce9e0f11e30793</originalsourceid><addsrcrecordid>eNqNksFu1DAQhiMEolXpC3BAfoFdbCdOHIGQ6EKhUiUuReJmTe1J1isnXtne3e5rceQheCacBip6QfhiyzP_N-PxXxQvGV0yyurXm6U2aVhyyumSiiWl4klxyoVsF1Sw6mk-01YspOTfTorzGDeUZpVgrObPi5Myr5o1_LT4ceFHJAOE4A9kwIijXh8HcCQmHIhG50gKMMatgzFBsn4kxh_GgP3OQcJIciAOQBzu0REYDUnrzLM6-N5ZIHi3DRjjpPPdjOp8GOzYkz6XTGvSgU4-kJ_fGbHjvRr0LiHZriHiJNIY8DbklrQPCe-IjXqNg4UXxbMOXMTz3_tZ8fXy483q8-L6y6er1fvrha6kpAtdC1EaKBEaA9BSVnatZg1K0MikbgGElp1uBedGlqbUVauxRdoxhiVt2vKsuJq5xsNGbYPN0zoqD1bdX_jQKwjJaofKsMw2phFVjZVsECrBq6atq7IFTiXNrHcza7u7HdBoHPNI3CPo48ho16r3e9U0vGVMZgCfAXnAMQbsHrSMqskYaqMmY6jJGIoKlY2RRa_-rvog-WODnPBmTjhYh8f_QKrVh5vy4jKfqulRb2c15l_YWwwqapuNhMYG1CmPyf6ru19QzuNC</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Bone marrow mesenchymal stem cell transplantation downregulates plasma level and the microglia expression of transforming growth factor β1 in the acute phase of cerebral cortex ischemia</title><source>Publicly Available Content Database</source><source>Wiley Open Access</source><source>PubMed Central</source><creator>Liang, Zhao-Hui ; Gu, Jian-Juan ; Yu, Wen-Xiu ; Guan, Yun-Qian ; Khater, Mostafa ; Li, Xiao-Bo</creator><creatorcontrib>Liang, Zhao-Hui ; Gu, Jian-Juan ; Yu, Wen-Xiu ; Guan, Yun-Qian ; Khater, Mostafa ; Li, Xiao-Bo</creatorcontrib><description>Both bone marrow mesenchymal stem cell (BM-MSC) and transforming growth factor-β1 (TGF-β1) have a strong anti-inflammatory capacity in stroke. But their relationship has not been well addressed. In this study, we investigated how intravenous BM-MSC transplantation in rats effected the expression of TGF-β1 48 h post cerebral ischemia, and we analyzed the main cells that produce TGF-β1. We used a distal middle cerebral artery occlusion (dMCAO) model in twenty Sprague–Dawley (SD) rats. The rats were randomly divided into two groups: the ischemic control group and the postischemic BM-MSC transplantation group. One hour after the dMCAO model was established, the rats were injected in the tail vein with either 1 ml saline or 1 × 106 BM-MSCs suspended in 1 ml saline. ELISAs were used to detect TGF-β1 content in the brain infarct core area, striatum and the plasma at 48 h after cerebral infarction. Immunofluorescent staining of brain tissue sections for TGF-β1, Iba-1, CD68 and NeuN was performed to determine the number and the proportion of double stained cells and to detect possible TGF-β1 producing cells in the brain tissue. Forty-eight hours after ischemia, the TGF-β1 content in the infarcted area of the BM-MSC transplantation group (23.94 ± 4.48 pg/ml) was significantly lower than it was in the ischemic control group (34.18 ± 4.32 pg/ml) (F = 13.534, P = 0.006). The TGF-β1 content in the rat plasma in the BM-MSC transplantation group (75.91 ± 12.53 pg/ml) was significantly lower than it was in the ischemic control group (131.18 ± 16.07 pg/ml) (F = 36.779, P = 0.0002), suggesting that after transplantation of BM-MSCs, TGF-β1 levels in the plasma decreased, but there was no significant change in the striatum area. Immunofluorescence staining showed that the total number of nucleated cells (1037.67 ± 222.16 cells/mm2) in the infarcted area after transplantation was significantly higher than that in the ischemic control group (391.67 ± 69.50 cells/mm2) (F = 92.421, P &lt; 0.01); the number of TGF-β1+ cells after transplantation (35.00 ± 13.66 cells/mm2) was significantly reduced in comparison to that in the ischemic control group (72.33 ± 32.08 cells/mm2) (F = 37.680, P &lt; 0.01). The number of TGF-β1+/Iba-1+ microglia cells in the transplantation group (3.67 ± 3.17 cells/mm2) was significantly reduced in comparison to that of the ischemic control group (13.67 ± 5.52 cells/mm2) (F = 29.641, P &lt; 0.01). The proportion of TGF-β1+/Iba-1+ microglia cells out of all Iba-1+ microglia cells after transplantation (4.38 ± 3.18%) was significantly decreased compared with that in the ischemic control group (12.81 ± 4.86%) (F = 28.125, P &lt; 0.01). Iba-1+ microglia is one of the main cell types that express TGF-β1. Intravenous transplantation of BM-MSCs does not cooperate with TGF-β1+ cells in immune-regulation, but reduces the TGF-β1 content in the infarcted area and in the plasma at 48 h after cerebral infarction.</description><identifier>ISSN: 2095-882X</identifier><identifier>ISSN: 2589-0514</identifier><identifier>EISSN: 2589-0514</identifier><identifier>DOI: 10.1016/j.cdtm.2020.05.005</identifier><identifier>PMID: 33336172</identifier><language>eng</language><publisher>United States: Elsevier B.V</publisher><subject>Cerebral infarction ; Mesenchymal stem cell ; Microglia ; Original ; Transforming growth factor-β1 ; Transplantation</subject><ispartof>Chronic diseases and translational medicine, 2020-12, Vol.6 (4), p.270-280</ispartof><rights>2020 Chinese Medical Association</rights><rights>2020 The Authors. Chronic Diseases and Translational Medicine published by John Wiley &amp; Sons, Ltd on behalf of Chinese Medical Association</rights><rights>2020 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.</rights><rights>2020 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. 2020 Chinese Medical Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4880-c6553da3ea7daa9013f9c17e8ace18c9aa5c8fc9522d83d3c49ce9e0f11e30793</citedby><cites>FETCH-LOGICAL-c4880-c6553da3ea7daa9013f9c17e8ace18c9aa5c8fc9522d83d3c49ce9e0f11e30793</cites><orcidid>0000-0001-7080-6534</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729118/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729118/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11562,27924,27925,46052,46476,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33336172$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liang, Zhao-Hui</creatorcontrib><creatorcontrib>Gu, Jian-Juan</creatorcontrib><creatorcontrib>Yu, Wen-Xiu</creatorcontrib><creatorcontrib>Guan, Yun-Qian</creatorcontrib><creatorcontrib>Khater, Mostafa</creatorcontrib><creatorcontrib>Li, Xiao-Bo</creatorcontrib><title>Bone marrow mesenchymal stem cell transplantation downregulates plasma level and the microglia expression of transforming growth factor β1 in the acute phase of cerebral cortex ischemia</title><title>Chronic diseases and translational medicine</title><addtitle>Chronic Dis Transl Med</addtitle><description>Both bone marrow mesenchymal stem cell (BM-MSC) and transforming growth factor-β1 (TGF-β1) have a strong anti-inflammatory capacity in stroke. But their relationship has not been well addressed. In this study, we investigated how intravenous BM-MSC transplantation in rats effected the expression of TGF-β1 48 h post cerebral ischemia, and we analyzed the main cells that produce TGF-β1. We used a distal middle cerebral artery occlusion (dMCAO) model in twenty Sprague–Dawley (SD) rats. The rats were randomly divided into two groups: the ischemic control group and the postischemic BM-MSC transplantation group. One hour after the dMCAO model was established, the rats were injected in the tail vein with either 1 ml saline or 1 × 106 BM-MSCs suspended in 1 ml saline. ELISAs were used to detect TGF-β1 content in the brain infarct core area, striatum and the plasma at 48 h after cerebral infarction. Immunofluorescent staining of brain tissue sections for TGF-β1, Iba-1, CD68 and NeuN was performed to determine the number and the proportion of double stained cells and to detect possible TGF-β1 producing cells in the brain tissue. Forty-eight hours after ischemia, the TGF-β1 content in the infarcted area of the BM-MSC transplantation group (23.94 ± 4.48 pg/ml) was significantly lower than it was in the ischemic control group (34.18 ± 4.32 pg/ml) (F = 13.534, P = 0.006). The TGF-β1 content in the rat plasma in the BM-MSC transplantation group (75.91 ± 12.53 pg/ml) was significantly lower than it was in the ischemic control group (131.18 ± 16.07 pg/ml) (F = 36.779, P = 0.0002), suggesting that after transplantation of BM-MSCs, TGF-β1 levels in the plasma decreased, but there was no significant change in the striatum area. Immunofluorescence staining showed that the total number of nucleated cells (1037.67 ± 222.16 cells/mm2) in the infarcted area after transplantation was significantly higher than that in the ischemic control group (391.67 ± 69.50 cells/mm2) (F = 92.421, P &lt; 0.01); the number of TGF-β1+ cells after transplantation (35.00 ± 13.66 cells/mm2) was significantly reduced in comparison to that in the ischemic control group (72.33 ± 32.08 cells/mm2) (F = 37.680, P &lt; 0.01). The number of TGF-β1+/Iba-1+ microglia cells in the transplantation group (3.67 ± 3.17 cells/mm2) was significantly reduced in comparison to that of the ischemic control group (13.67 ± 5.52 cells/mm2) (F = 29.641, P &lt; 0.01). The proportion of TGF-β1+/Iba-1+ microglia cells out of all Iba-1+ microglia cells after transplantation (4.38 ± 3.18%) was significantly decreased compared with that in the ischemic control group (12.81 ± 4.86%) (F = 28.125, P &lt; 0.01). Iba-1+ microglia is one of the main cell types that express TGF-β1. Intravenous transplantation of BM-MSCs does not cooperate with TGF-β1+ cells in immune-regulation, but reduces the TGF-β1 content in the infarcted area and in the plasma at 48 h after cerebral infarction.</description><subject>Cerebral infarction</subject><subject>Mesenchymal stem cell</subject><subject>Microglia</subject><subject>Original</subject><subject>Transforming growth factor-β1</subject><subject>Transplantation</subject><issn>2095-882X</issn><issn>2589-0514</issn><issn>2589-0514</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>DOA</sourceid><recordid>eNqNksFu1DAQhiMEolXpC3BAfoFdbCdOHIGQ6EKhUiUuReJmTe1J1isnXtne3e5rceQheCacBip6QfhiyzP_N-PxXxQvGV0yyurXm6U2aVhyyumSiiWl4klxyoVsF1Sw6mk-01YspOTfTorzGDeUZpVgrObPi5Myr5o1_LT4ceFHJAOE4A9kwIijXh8HcCQmHIhG50gKMMatgzFBsn4kxh_GgP3OQcJIciAOQBzu0REYDUnrzLM6-N5ZIHi3DRjjpPPdjOp8GOzYkz6XTGvSgU4-kJ_fGbHjvRr0LiHZriHiJNIY8DbklrQPCe-IjXqNg4UXxbMOXMTz3_tZ8fXy483q8-L6y6er1fvrha6kpAtdC1EaKBEaA9BSVnatZg1K0MikbgGElp1uBedGlqbUVauxRdoxhiVt2vKsuJq5xsNGbYPN0zoqD1bdX_jQKwjJaofKsMw2phFVjZVsECrBq6atq7IFTiXNrHcza7u7HdBoHPNI3CPo48ho16r3e9U0vGVMZgCfAXnAMQbsHrSMqskYaqMmY6jJGIoKlY2RRa_-rvog-WODnPBmTjhYh8f_QKrVh5vy4jKfqulRb2c15l_YWwwqapuNhMYG1CmPyf6ru19QzuNC</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Liang, Zhao-Hui</creator><creator>Gu, Jian-Juan</creator><creator>Yu, Wen-Xiu</creator><creator>Guan, Yun-Qian</creator><creator>Khater, Mostafa</creator><creator>Li, Xiao-Bo</creator><general>Elsevier B.V</general><general>Chinese Medical Association</general><general>Wiley</general><scope>6I.</scope><scope>AAFTH</scope><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7080-6534</orcidid></search><sort><creationdate>202012</creationdate><title>Bone marrow mesenchymal stem cell transplantation downregulates plasma level and the microglia expression of transforming growth factor β1 in the acute phase of cerebral cortex ischemia</title><author>Liang, Zhao-Hui ; Gu, Jian-Juan ; Yu, Wen-Xiu ; Guan, Yun-Qian ; Khater, Mostafa ; Li, Xiao-Bo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4880-c6553da3ea7daa9013f9c17e8ace18c9aa5c8fc9522d83d3c49ce9e0f11e30793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cerebral infarction</topic><topic>Mesenchymal stem cell</topic><topic>Microglia</topic><topic>Original</topic><topic>Transforming growth factor-β1</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liang, Zhao-Hui</creatorcontrib><creatorcontrib>Gu, Jian-Juan</creatorcontrib><creatorcontrib>Yu, Wen-Xiu</creatorcontrib><creatorcontrib>Guan, Yun-Qian</creatorcontrib><creatorcontrib>Khater, Mostafa</creatorcontrib><creatorcontrib>Li, Xiao-Bo</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Wiley Open Access</collection><collection>Wiley Free Archive</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Chronic diseases and translational medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liang, Zhao-Hui</au><au>Gu, Jian-Juan</au><au>Yu, Wen-Xiu</au><au>Guan, Yun-Qian</au><au>Khater, Mostafa</au><au>Li, Xiao-Bo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bone marrow mesenchymal stem cell transplantation downregulates plasma level and the microglia expression of transforming growth factor β1 in the acute phase of cerebral cortex ischemia</atitle><jtitle>Chronic diseases and translational medicine</jtitle><addtitle>Chronic Dis Transl Med</addtitle><date>2020-12</date><risdate>2020</risdate><volume>6</volume><issue>4</issue><spage>270</spage><epage>280</epage><pages>270-280</pages><issn>2095-882X</issn><issn>2589-0514</issn><eissn>2589-0514</eissn><abstract>Both bone marrow mesenchymal stem cell (BM-MSC) and transforming growth factor-β1 (TGF-β1) have a strong anti-inflammatory capacity in stroke. But their relationship has not been well addressed. In this study, we investigated how intravenous BM-MSC transplantation in rats effected the expression of TGF-β1 48 h post cerebral ischemia, and we analyzed the main cells that produce TGF-β1. We used a distal middle cerebral artery occlusion (dMCAO) model in twenty Sprague–Dawley (SD) rats. The rats were randomly divided into two groups: the ischemic control group and the postischemic BM-MSC transplantation group. One hour after the dMCAO model was established, the rats were injected in the tail vein with either 1 ml saline or 1 × 106 BM-MSCs suspended in 1 ml saline. ELISAs were used to detect TGF-β1 content in the brain infarct core area, striatum and the plasma at 48 h after cerebral infarction. Immunofluorescent staining of brain tissue sections for TGF-β1, Iba-1, CD68 and NeuN was performed to determine the number and the proportion of double stained cells and to detect possible TGF-β1 producing cells in the brain tissue. Forty-eight hours after ischemia, the TGF-β1 content in the infarcted area of the BM-MSC transplantation group (23.94 ± 4.48 pg/ml) was significantly lower than it was in the ischemic control group (34.18 ± 4.32 pg/ml) (F = 13.534, P = 0.006). The TGF-β1 content in the rat plasma in the BM-MSC transplantation group (75.91 ± 12.53 pg/ml) was significantly lower than it was in the ischemic control group (131.18 ± 16.07 pg/ml) (F = 36.779, P = 0.0002), suggesting that after transplantation of BM-MSCs, TGF-β1 levels in the plasma decreased, but there was no significant change in the striatum area. Immunofluorescence staining showed that the total number of nucleated cells (1037.67 ± 222.16 cells/mm2) in the infarcted area after transplantation was significantly higher than that in the ischemic control group (391.67 ± 69.50 cells/mm2) (F = 92.421, P &lt; 0.01); the number of TGF-β1+ cells after transplantation (35.00 ± 13.66 cells/mm2) was significantly reduced in comparison to that in the ischemic control group (72.33 ± 32.08 cells/mm2) (F = 37.680, P &lt; 0.01). The number of TGF-β1+/Iba-1+ microglia cells in the transplantation group (3.67 ± 3.17 cells/mm2) was significantly reduced in comparison to that of the ischemic control group (13.67 ± 5.52 cells/mm2) (F = 29.641, P &lt; 0.01). The proportion of TGF-β1+/Iba-1+ microglia cells out of all Iba-1+ microglia cells after transplantation (4.38 ± 3.18%) was significantly decreased compared with that in the ischemic control group (12.81 ± 4.86%) (F = 28.125, P &lt; 0.01). Iba-1+ microglia is one of the main cell types that express TGF-β1. Intravenous transplantation of BM-MSCs does not cooperate with TGF-β1+ cells in immune-regulation, but reduces the TGF-β1 content in the infarcted area and in the plasma at 48 h after cerebral infarction.</abstract><cop>United States</cop><pub>Elsevier B.V</pub><pmid>33336172</pmid><doi>10.1016/j.cdtm.2020.05.005</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-7080-6534</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2095-882X
ispartof Chronic diseases and translational medicine, 2020-12, Vol.6 (4), p.270-280
issn 2095-882X
2589-0514
2589-0514
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_d1f9cdd7546e487ea4524796439a2080
source Publicly Available Content Database; Wiley Open Access; PubMed Central
subjects Cerebral infarction
Mesenchymal stem cell
Microglia
Original
Transforming growth factor-β1
Transplantation
title Bone marrow mesenchymal stem cell transplantation downregulates plasma level and the microglia expression of transforming growth factor β1 in the acute phase of cerebral cortex ischemia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T19%3A06%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bone%20marrow%20mesenchymal%20stem%20cell%20transplantation%20downregulates%20plasma%20level%20and%20the%20microglia%20expression%20of%20transforming%20growth%20factor%20%CE%B21%20in%20the%20acute%20phase%20of%20cerebral%20cortex%20ischemia&rft.jtitle=Chronic%20diseases%20and%20translational%20medicine&rft.au=Liang,%20Zhao-Hui&rft.date=2020-12&rft.volume=6&rft.issue=4&rft.spage=270&rft.epage=280&rft.pages=270-280&rft.issn=2095-882X&rft.eissn=2589-0514&rft_id=info:doi/10.1016/j.cdtm.2020.05.005&rft_dat=%3Cwiley_doaj_%3ECDT3BF00540%3C/wiley_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4880-c6553da3ea7daa9013f9c17e8ace18c9aa5c8fc9522d83d3c49ce9e0f11e30793%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/33336172&rfr_iscdi=true